ArticleDiscover oncology2025
Immunoregulatory role of pulmonary microbiota in lung cancer: a bibliometric analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study systematically analyzes the research landscape of lung cancer and pulmonary microbiota from 2015 to 2024 using bibliometric methods.
methodsThe Web of Science Core Collection provided data analyzed to uncover key contributors, pivotal research hotspots, and evolving trends.
resultsResults revealed a significant shift in focus from infections and inflammation to immunotherapy, microbial biomarkers, and immune response modulation, reflecting interplay between pulmonary microbiota and immune regulation in tumorigenesis. Major contributors, including China and the United States, along with leading journals, have driven progress in this interdisciplinary field, highlighting microbial imbalance's involvement in tumorigenesis and immune modulation. The findings underscore the potential of pulmonary microbiota as therapeutic targets and immune modulators, particularly for improving immunotherapy outcomes.
conclusionsThis study provides a comprehensive overview of the field, offering insights into its current status and future directions, and establishes a foundation for further exploration of personalized medicine and immune-centered therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.